This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
JM Davis , N Chen (2001). The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. Journal of Clinical Psychiatry 62, 757–771.
J Geddes , N Freemantle , P Harrison , P Bebbington (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321, 1371–1376.
S Heres , J Davis , K Maino , E Jetzinger , W Kissling , S Leucht (2006). Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 163, 185–194.
OJ Hoyberg , C Fensbo , J Remvig , O Lingjaerde , M Sloth-Nielsen , I Salvesen (1993). Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatrica Scandinavica 88, 395–402.
PB Jones , TRE Barnes , L Davies , G Dunn , H Lloyd , KP Hayhurst , RM Murray , A Markwick , SW Lewis (2006). Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63, 1079–1086.
S Kasper , D Winkler (2006). Addressing the limitations of the CATIE study. World Journal of Biological Psychiatry 7, 126–127.
S Leucht , C Corves , D Arbter , RR Engel , C Li , JM Davis (2009 a). Second-generation versus first-generation antipsychotics for schizophrenia: a meta-analysis. Lancet 373, 31–41.
S Leucht , RR Engel , J Bauml , JM Davis (2007). Is the superior efficacy of new generation antipsychotics an artifact of LOCF? Schizophrenia Bulletin 33, 183–191.
SW Lewis , TR Barnes , L Davies , RM Murray , G Dunn , KP Hayhurst , A Markwick , H Lloyd , PB Jones (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32, 715–723.
JA Mattes (1997). Risperidone: how good is the evidence for efficacy? Schizophrenia Bulletin 23, 155–161.
R Rosenheck , D Perlick , S Bingham , W Liu-Mares , J Collins , S Warren , D Leslie , E Allan , EC Campbell , S Caroff , J Corwin , L Davis , R Douyon , L Dunn , D Evans , E Frecska , J Grabowski , D Graeber , L Herz , K Kwon , W Lawson , F Mena , J Sheikh , D Smelson , V Smith-Gamble (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Journal of the American Medical Association 290, 2693–2702.
H Scherk , FG Pajonk , S Leucht (2007). Second-generation antipsychotics in the treatment of acute mania: a systematic review and meta-analysis of randomized, controlled trials. Archives of General Psychiatry 64, 442–455.
N Schooler , J Rabinowitz , M Davidson , R Emsley , PD Harvey , L Kopala , PD McGorry , I Van Hove , M Eerdekens , W Swyzen , G De Smedt (2005). Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. American Journal of Psychiatry 162, 947–953.
WO Tarnow-Mordi , MJ Healy (1999). Distinguishing between ‘no evidence of effect’ and ‘evidence of no effect’ in randomised controlled trials and other comparisons. Archives of Disease in Childhood 80, 210–211.